Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

NCT04531813 | Completed Phase 3 Results FDA Drug

• 1 other identifier: 18153
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

In this study researchers want to study the potential skin reaction after repeated application of an antifungal cream containing trolamine. The study plans to enroll about 32 healthy female or male participants with the age 18 - 79 years. Researchers will apply on the skin of the upper back between the shoulder blades of the study participants three different patches to cover a small amount of the antifungal cream or 0.3% solution of sodium lauryl sulfate, which is known to cause skin irritation (so called positive control). A third patch will cover a skin area without any product (so called negative control). Participants will return daily to the study center to have new patches containing the test products applied on the same skin area of the back, excluding weekends, for 21 days of continuous skin contact. At each visit the skin will be investigated by the researchers for redness, dryness and other reactions to learn about the skin reaction after repeated application.

Conditions

Hypersensitivity

Outcome Measures

Primary Outcomes (1)

• Cumulative Irritation Total (CIT) Score

  Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: 0 = No visible erythema; 0.5 = Slight, barely perceptible erythema; 1 = Mild erythema; 2 = Moderate erythema; 3 = Marked erythema; 4 = Severe erythema. The Cumulative Irritation Total is generated by totaling the Erythema Scoring Scale scores of the Investigational Product for each subject completing the trial and then adding those totals. Data is being reported for all the 30 participants as a group.

  21 days

Study Arms (1)

Cumulative Irritation Test

EXPERIMENTAL

Participants received butenafine HCl 1% cream on the skin test site, 0.3% solution of sodium lauryl sulfate on the skin Positive Control test site, and a blank patch on the skin Negative Control test site daily (excluding weekends) for 21 days, or 15 applications.

Drug: Butenafine HCl 1% (BAY1896425); Drug: Positive Control-Sodium lauryl sulfate (SLS); Other: Negative Control

Interventions

Butenafine HCl 1% (BAY1896425) DRUG

Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.

Also known as: Antifungal Cream V61-044 containing Trolamine

Cumulative Irritation Test

Positive Control-Sodium lauryl sulfate (SLS) DRUG

Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.

Cumulative Irritation Test

Negative Control OTHER

A blank patch was applied to the Negative Control test site.

Cumulative Irritation Test

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must have been aged 18 to 79 years, inclusive.
• Participants must have understood and executed an Informed Consent Form (ICF).
• Participants (if female) must have been willing to take a urine pregnancy test prior to the initiation and at the completion of the trial.
• Participants must have been capable of understanding and following directions.
• Participants must have been considered reliable.

You may not qualify if:

• Participants who were in ill health or taking medication, other than birth control, which could have influenced the purpose, integrity or outcome of the trial.
• Participants who had any visible skin disease that might have been confused with a skin reaction to the test material.
• Participants who were participating in another clinical trial at this facility or any other facility.
• Participants who were using topical or systemic steroids or antihistamines for at least 7 days prior to trial initiation and during the duration of the trial.
• Participants who had a history of adverse reaction to adhesive tape, cosmetics, over-the-counter (OTC) drugs or other personal care products.
• Participants judged by the principal investigator (PI) to be inappropriate for the trial.
• Female participants who were pregnant as evidenced by a positive urine pregnancy test, planning to become pregnant, or nursing during the course of the trial.

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Unknown Facility

Fairfield, New Jersey, 07004, United States

Location

Related Links

• Click here to find results for studies related to Bayer Healthcare products.

MeSH Terms

Conditions

Hypersensitivity

Interventions

butenafine

Condition Hierarchy (Ancestors)

Immune System Diseases

Results Point of Contact

• Title: Therapeutic Area Head
• Organization: BAYER

clinical-trials-contact@bayer.com

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2020
• First Posted: August 31, 2020
• Study Start: June 10, 2013
• Primary Completion: July 1, 2013
• Study Completion: July 1, 2013
• Last Updated: September 25, 2020
• Results First Posted: September 25, 2020

Record last verified: 2020-09

Locations

US (1)